The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Unchanged in May: Crecon Report
July 8, 2015
- Sawai Gearing Up to Revise 3-Year Biz Plan after New Generic Target
July 8, 2015
- Towa to Issue Convertible Bonds with Face Value of 15 Billion Yen
July 8, 2015
- ASCO Immunotherapy Roundup - 1: Opdivo Data Boost Confidence in BMS’s Combination Strategy
July 7, 2015
- Series: ASCO Immunotherapy Roundup
July 7, 2015
- Japan, US, Europe Anti-Infective Agent Markets Grow 48.4% in FY2014 Driven by Anti-HCV Treatments: Survey
July 7, 2015
- Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
July 6, 2015
- Multiple Myeloma Treatment Farydak Approved: Novartis
July 6, 2015
- Once-Weekly GLP-1 Receptor Agonist Trulicity Approved: Eli Lilly Japan
July 6, 2015
- Idiopathic Pulmonary Fibrosis Treatment OFEV Approved: NBI
July 6, 2015
- Immune Checkpoint Inhibitor Yervoy Approved for Malignant Melanoma: Bristol-Myers
July 6, 2015
- Lupus Erythematosus Treatment Plaquenil Approved: Sanofi
July 6, 2015
- Hepatitis C Treatment Harvoni Approved: Gilead Sciences
July 6, 2015
- MTPC Preparing to Submit Radicut for an Indication of ALS in the US
July 3, 2015
- Santen Files IND Application for Anti-Endoglin Antibody for Wet AMD in US
July 3, 2015
- President Tada to Double as Drug Development Head: Sumitomo Dainippon
July 3, 2015
- JCR Aims at Growth through New Products, Out-Licensing Activities
July 2, 2015
- Merck Serono, Nippon Shinyaku to Copromote Gonalef
July 2, 2015
- Announcement: 2nd Annual Oncology Asia - Sheraton Miyako Hotel Tokyo, September 7-9
July 2, 2015
- Bayer Files for Regulatory Approval of Hemophilia A Treatment in Japan
July 1, 2015
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…